Sophiris Bio, Inc. is a biopharmaceutical entity currently in the clinical trial phase, dedicated to pioneering treatments for conditions affecting the urinary system. Its flagship investigational compound, PRX302 (topsalysin), is presently undergoing Phase III trials. This candidate is being evaluated for its efficacy in alleviating lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH) and for addressing localized low to intermediate risk prostate cancer. Sophiris has forged a strategic alliance with Kissei Pharmaceutical Co., Ltd. This collaboration encompasses the development and commercialization of PRX302 for a range of prostatic ailments, including BPH symptoms, prostate cancer, and prostatitis. Furthermore, the company holds licensing rights from UVIC Industry Partnerships Inc. and The Johns Hopkins University. These agreements pertain to the application of PRX302 in developing therapies for BPH symptoms, prostate cancer, and various other non-malignant prostate conditions. Originally established in 2002, the company operated as Protox Therapeutics Inc. before adopting the Sophiris Bio, Inc. name in April 2012. Its operations are headquartered in La Jolla, California.


Net sales
Gross margin
Net income